BOULDER, Colo., April 23 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed public offering of up to $40,000,000 of its common stock.
Banc of America Securities LLC will act as sole bookrunning manager for the offering. Needham & Company, LLC will act as co-lead manager and Rodman & Renshaw, LLC will act as co-manager for the offering. When available, copies of the preliminary prospectus related to the offering may be obtained from Banc of America Securities LLC, Attn: Prospectus Department, 100 West 33rd Street, New York, NY 10001 or via e-mail at dg.prospectus_distribution@bofasecurities.com.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. Further, this press release does not constitute either an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Tapestry Pharmaceuticals, Inc.
Tapestry Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer.
Contact: Tapestry Pharmaceuticals, Inc. Gordon Link Senior Vice President, Chief Financial Officer 303-516-8500 glink@tapestrypharma.com Elma Hawkins, Ph.D. Communications and Corporate Development 212-400-3019 ehawkins@tapestrypharma.com Investor: Lilian Stern Stern Investor Relations, Inc. 212-362-1200 lilian@sternir.com
Tapestry Pharmaceuticals, Inc.
CONTACT: Gordon Link, Senior Vice President, Chief Financial Officer,+1-303-516-8500, glink@tapestrypharma.com , or Elma Hawkins, Ph.D.,Communications and Corporate Development, +1-212-400-3019,ehawkins@tapestrypharma.com , both of Tapestry Pharmaceuticals, Inc.; orInvestors, Lilian Stern of Stern Investor Relations, Inc., +1-212-362-1200,lilian@sternir.com
